Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).
Lassman AB, Pugh SL, Gilbert MR, Aldape KD, Geinoz S, Beumer JH, Christner SM, Komaki R, DeAngelis LM, Gaur R, Youssef E, Wagner H, Won M, Mehta MP.
Lassman AB, et al. Among authors: wagner h.
Neuro Oncol. 2015 Jul;17(7):992-8. doi: 10.1093/neuonc/nov011. Epub 2015 Mar 10.
Neuro Oncol. 2015.
PMID: 25758746
Free PMC article.
Clinical Trial.